Flezelastine

Drug Profile

Flezelastine

Alternative Names: D 18024; IDB 18024

Latest Information Update: 20 Jan 2017

Price : $50

At a glance

  • Originator ASTA Medica [CEASED]
  • Developer ASTA Medica; ASTA Medica [CEASED]; Meda Pharmaceuticals; MedPointe; National Cancer Institute (USA); Nonindustrial source
  • Class Antiallergics; Antiasthmatics; Antihistamines; Azepines; Phthalazines
  • Mechanism of Action 5-lipoxygenase inhibitors; Calcium channel antagonists; Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Allergic rhinitis; Asthma; Cancer

Most Recent Events

  • 20 Jan 2017 Discontinued - Preclinical for Cancer in Germany (unspecified route)
  • 20 Jan 2017 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 11 Sep 1998 Discontinued-Preclinical in Cancer in Germany (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top